Sign In
Buy IPSC
$2.07
-0.100 (-4.61%)
At Close: Jun 03, 2026
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
07:00am, Thursday, 13'th Nov 2025
PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies f
Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference
04:01pm, Tuesday, 14'th Oct 2025
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies f
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Friday, 22'nd Aug 2025
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 14'th Aug 2025
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functiona
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
01:01pm, Monday, 21'st Jul 2025
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
09:50am, Tuesday, 15'th Jul 2025
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several s
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
09:50am, Wednesday, 25'th Jun 2025
Century Therapeutics (IPSC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
09:51am, Friday, 06'th Jun 2025
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several s
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
04:01pm, Wednesday, 28'th May 2025
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
09:16pm, Thursday, 15'th May 2025
Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a yea
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 15'th May 2025
PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:07am, Thursday, 01'st May 2025
Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
04:30pm, Monday, 28'th Apr 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cel
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 25'th Mar 2025
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates
06:15pm, Wednesday, 19'th Mar 2025
Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago.
